An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

GrГјnwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I Eur J Cancer. 2012 Feb,48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29.

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D. Crit Rev Oncol Hematol. 2012 Jun,82(3):370-7. doi: 10.1016/j.critrevonc.2011.08.002. Epub 2011 Sep 7.

First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.

Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M. J Cancer Res Clin Oncol. 2012 Jan,138(1):65-72. doi: 10.1007/s00432-011-1061-6. Epub 2011 Sep 30.

Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.

Jöhrer K, Obkircher M, Neureiter D, Parteli J, Zelle-Rieser C, Maizner E, Kern J, Hermann M, Hamacher F, Merkel O, Wacht N, Zidorn C, Scheideler M, Greil R. J Mol Med (Berl). 2012 Jun,90(6):681-93. doi: 10.1007/s00109-011-0848-x. Epub 2011 Dec 29.

Prognostic value of number of removed lymph nodes, number of involved lymph nodes and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M. Ann Surg Oncol. 2012 Jun,19(6):1808-17. doi: 10.1245/s10434-011-2189-y. Epub 2011 Dec 30.

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y, Marks S J Antimicrob Chemother. 2012 Mar,67(3):685-90. doi: 10.1093/jac/dkr533. Epub 2011 Dec 29.

Treating T-cell lymphoma: is there a light at the end of the tunnel?

Hopfinger, G, Merkel, O, Melchardt, T, Greil, R, Magazine of European Medical Oncology. 2012, 5 (3): 174-177.

Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.

von Tresckow B, PlГјtschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A. J Clin Oncol. 2012 Mar 20,30(9):907-13. doi: 10.1200/JCO.2011.38.5807. Epub 2012 Jan 23.

Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.

Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M. J Clin Oncol. 2012 Mar 1,30(7):722-8. doi: 10.1200/JCO.2011.36.8993. Epub 2012 Jan 23.

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C. J Clin Oncol. 2012 Mar 20,30(9):921-9. doi: 10.1200/JCO.2011.35.7376. Epub 2012 Feb 13.